Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): A double-blind placebo-controlled trial

Journal of the American Heart Association

Volumn 2, Issue 3, 2013, Pages

  Mihai, Georgeta ^a   Varghese, Juliet ^a   Kampfrath, Thomas ^a   Gushchina, Liubov ^a   Hafer, Lisa ^a   Deiuliis, Jeffrey ^a   Maiseyeu, Andrei ^a   Simonetti, Orlando P ^a   Lu, Bo ^a   Rajagopalan, Sanjay ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Atherosclerosis; Magnetic resonance imaging; Renin

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RENIN INHIBITOR; AMIDE; FUMARIC ACID DERIVATIVE; RENIN;

ABDOMINAL AORTA; ADULT; ARTERIAL WALL VOLUME; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL PARAMETERS; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TREATMENT FAILURE; FEMALE; HIGH RISK PATIENT; HUMAN; MAINTENANCE DRUG DOSE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORACIC AORTA; THREE DIMENSIONAL IMAGING; TREATMENT DURATION; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; MIDDLE AGED; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; ANTAGONISTS AND INHIBITORS; COMPLICATION; PLAQUE, ATHEROSCLEROTIC;

ATHEROSCLEROSIS; MAGNETIC RESONANCE IMAGING; RENIN;

AMIDES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FUMARATES; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; RENIN; SINGLE-BLIND METHOD;

EID: 84887627758     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.112.004879     Document Type: Article

References (34)

1. Dzau VJ. Theodore Cooper Lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047-1052.
2. Nguyen Dinh Cat A, Touyz RM. A new look at the renin-angiotensin system - focusing on the vascular system. Peptides. 2011;32:2141-2150.
3. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [see comments] [published erratum appears in N Engl J Med 2000;342:748]. N Engl J Med. 2000;342:145-153.
4. Dahl€of B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
5. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-256.
6. Fisher ND, Meagher EA. Renin inhibitors. J Clin Hypertens (Greenwich). 2011;13:662-666.
7. Lu H, Rateri DL, Feldman DL Jr, Fukamizu A, Ishida J, Oesterling EG, Cassis LA, Daugherty A. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Investig. 2008;118:984-993.
8. Verma S, Gupta MK. Aliskiren improves nitric oxide bioavailability and limits atherosclerosis. Hypertension. 2008;52:467-469.
9. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension. 2008;51:1306-1311.
10. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351: 2058-2068.
11. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907-917.
12. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
13. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953-957.
14. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves JW, Hill MN, Jones DH, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. J Clin Hypertens (Greenwich). 2005;7:102-109.
15. Chou TC. Electrocardiography in Clinical Practice. Philadelphia, PA: WB Saunders; 1991.
16. Mihai G, Chung YC, Merchant A, Simonetti OP, Rajagopalan S. T1-weighted-SPACE dark blood whole body magnetic resonance angiography (DB-WBMRA): initial experience. J Magn Reson Imaging. 2010;31:502-509.
17. Mihai G, Chung YC, Kariisa M, Raman SV, Simonetti OP, Rajagopalan S. Initial feasibility of a multi-station high resolution three-dimensional dark blood angiography protocol for the assessment of peripheral arterial disease. J Magn Reson Imaging. 2009;30:785-793.
18. Yonemura A, Momiyama Y, Fayad ZA, Ayaori M, Ohmori R, Kihara T, Tanaka N, Nakaya K, Ogura M, Taniguchi H, Kusuhara M, Nagata M, Nakamura H, Tamai S, Ohsuzu F. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques: a 2-year follow-up by noninvasive MRI. Eur J Cardiovasc Prev Rehabil. 2009;16:222-228.
19. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
20. West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, Berr SS, Harthun NL, DiMaria JM, Hunter JR, Christopher JM, Chew JD, Winberry GB, Kramer CM. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011;218:156-162.
21. Nicholls SJ, Sipahi I, Schoenhagen P, Crowe T, Tuzcu EM, Nissen SE. Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat Rev Drug Discov. 2006;5:485-492.
22. Momiyama Y, Fayad ZA. Aortic plaque imaging and monitoring atherosclerotic plaque interventions. Top Magn Reson Imaging. 2007;18:349-355.
23. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: siteselective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol. 2004;24:12-22.
24. Hayashi K, Mani V, Nemade A, Aguiar S, Postley JE, Fuster V, Fayad ZA. Variations in atherosclerosis and remodeling patterns in aorta and carotids. J Cardiovasc Magn Reson. 2010;12:10.
25. Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451:904-913.
26. Wannamethee SG, Lowe GD, Rumley A, Cherry L, Whincup PH, Sattar N. Adipokines and risk of type 2 diabetes in older men. Diabetes Care. 2007;30:1200-1205.
27. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of scotland coronary prevention study (WOSCOPS). Circulation. 2001;104: 3052-3056.
28. Wallerstedt SM, Eriksson AL, Niklason A, Ohlsson C, Hedner T. Serum leptin and myocardial infarction in hypertension. Blood Press. 2004;13:243-246.
29. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008;117:3238-3249.
30. Ruige JB, Dekker JM, Blum WF, Stehouwer CD, Nijpels G, Mooy J, Kostense PJ, Bouter LM, Heine RJ. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. The Hoorn Study. Diabetes Care. 1999;22:1097-1104.
31. Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20:1-6.
32. Rabelo LA, Alenina N, Bader M. ACE2-angiotensin-(1-7)-Mas axis and oxidative stress in cardiovascular disease. Hypertens Res. 2011;34:154-160.
33. Azizi M, Menard J. Renin inhibitors and cardiovascular and renal protection: an endless quest? Cardiovasc Drugs Ther. 2012 Mar 6. [Epub ahead of print] doi: 10.1007/s10557-012-6380-6.
34. McMurray JJ, Abraham WT, Dickstein K, Kober L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012; 14:341-343.